|
|
|
|
|
|
by missedthecue
1368 days ago
|
|
|
According to the article, it occured between 2009 and 2014. Not sure exactly how much profit they made off of it and it's probably not easy to find out, but of the three drugs they marketed in unlawful ways, Tysabri for instance had US sales of $58m in the 08-09 year. And that's sales not pure profit after costs. |
|
|
2010-June-30: $1094M
2011-June-30: $1076M
2012-June-30: $1342M
2013-June-30: $1608M
2014-June-30: $2140M
2015-June-30: $3490M
Also, because someone asked, edgar has a bar chart breakdown of Biogen's product revenue. The lawsuit was about Biogen's drugs Avonex, Tysabri and Tecfidera. The bar chart (https://www.sec.gov/Archives/edgar/data/875045/0000875045150...) seems to indicate that these three were responsible for about 80-83% of Biogen's revenues (and presumably net income?) in 2014.
I guess what we don't know is what their sales would have been like without the kickbacks? Less, presumably? But 0? Probably not.